<DOC>
	<DOCNO>NCT01226043</DOCNO>
	<brief_summary>Primary Objective : To assess patient preference Lantus SoloSTAR pen versus Lantus vial syringe end Crossover Phase ( Week 4 ) patient type 2 diabetes mellitus ( T2DM ) Secondary Objectives : To compare Lantus SoloSTAR pen versus Lantus vial syringe regard follow parameter : Randomization/Crossover phase : - Healthcare professional 's ( HCP ) recommendation Lantus SoloSTAR pen versus Lantus vial syringe Re-randomization phase : - Change Fasting Plasma Glucose ( FPG ) week 4 week 10 - Percentage patient achieve FPG &lt; 110 mg/dL week 10 - Change Lantus dose inject per day ( U ) week 4 week 10 Observational phase : - Percentage patient achieve glycosylated hemoglobin ( HbA1c ) goal ( &lt; 7 % ) week 40 - Time first observation HbA1c &lt; 7 % observational phase - Percentage patient discontinue Investigational Product ( IP ) observational phase due dissatisfaction current device All phase : - Percentage patient discontinue IP phase study - Safety assessment occurrence hypoglycemic event ( HE ) adverse event ( AE )</brief_summary>
	<brief_title>Patient Preference Satisfaction With Insulin Glargine ( Lantus ) Solostar Pen vs Conventional Vial-Syringe Method Lantus Injection Therapy Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This study consist 1 week Screening Phase , 4-week Randomization/Crossover Phase , 6-week Re-randomization Phase , follow 30 week Observational Phase . The total duration study participation 41 week total treatment duration 40 week Lantus exposure .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Patients confirm diagnosis type 2 diabetes mellitus treat combination 2 3 oral antidiabetic drug ( OADs ) stable dose precede 3 month , include limited : Metformin + sulfonylurea + thiazolidinedione ( Pioglitazone ) Metformin + sulfonylurea Metformin + thiazolidinedione ( Pioglitazone ) Metformin + dipeptidyl peptidase ( DPPIV ) And Investigator/treating physician decide basal insulin appropriate . Patients sign Informed Consent Form Health Insurance Portability Accountability Act ( HIPAA ) Authorization Form Exclusion criterion : Patients le 18 year great 85 year age ( ie , reach age 86 screen visit ) Patients confirm diagnosis type 1 diabetes mellitus Patients treat insulin treat insulin precede 12 month exception insulin treatment hospitalization ( ie , patient receive insulin hospitalize could include ) Patients whose screen HbA1c &lt; 7 % &gt; 10 % Patients current addiction current alcohol / drug abuse Patients cardiac status New York Heart Association IIIIV Patients stroke , myocardial infarction , coronary artery bypass graft , percutaneous transluminal coronary angioplasty , unstable angina pectoris within 12 month prior screen Patients diagnosis dementia , severe visual dexterity impairment Patients malignancy within last 5 year , exception adequately treat basal squamous cell carcinoma skin adequately treat cervical carcinoma situ Patients concomitant disease concomitant medication could interfere treatment ability answer questionnaires Patients unable selfinject Patients take treated Byetta® ( exenatide ) GlucagonLike Peptide1 agonist within 3 month screen : Patients pregnant breastfeed Women childbearing potential protect highly effective contraceptive method birth control ( define contraception Informed Consent Form /or local protocol addendum ) and/or unwilling unable tested pregnancy Patients impaired renal function show serum creatinine ≥1.5 mg/dL male ≥1.4 mg/dL female screen Patients clinical evidence active liver disease , serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) 2.5 time upper limit normal range ( ULN ) Patients unlikely comply protocol requirement ( eg , illiterate , uncooperative , unable return schedule visit , unlikely complete study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>